Jakafi PV launch pushes up Incyte's 1Q sales
This article was originally published in Scrip
Incyte's AK 1 and 2 tyrosine kinase inhibitor, Jakafi (ruxolitinib), has beaten expectations in the first quarter of 2015 following the launch of the product in new indication polycythemia vera.
You may also be interested in...
CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...